A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

NCT05199272 ↗

Phase 1/2 Active not recruiting 141 enrolled 23andMe, Inc.

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by intravenous infusion in patients with advanced solid malignancies who have progressed on all available standard therapies

Timeline

Start: 2021-12-29
Primary completion: 2025-03
Completion: 2025-03

Publications

Kummar S, Razak AA, Laurie S, Glatt DM, Kell S, Diep AN, Schmidt M, Hom C, German C, Shringarpure SS, Majeed SR, Rasco D. First-in-Human Study of 23ME-00610, an Antagonistic Antibody for Genetically Validated CD200R1 Immune Checkpoint, in Participants with Advanced Solid Malignancies. Cancer Res Commun. 2025 Jan 1;5(1):94-105. doi: 10.1158/2767-9764.CRC-24-0568.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	23ME-00610	Monoclonal antibody	2 mg	Intravenous
Subject	23ME-00610	Monoclonal antibody	1400 mg	Intravenous

A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies

Summary

Timeline

Publications

Drugs

Indications